Abstract
Currently, research for hematological malignancies is very intensive, with many breakthroughs. Among them, aptamer-based targeted therapies could be counted. Aptamer is a targeting tool with many unique advantages (easy synthesis, low toxicity, easy modification, low immunogenicity, nano size, long stability, etc.), therefore many experts screened corresponding aptamers in various hematological malignancies for diagnosis and treatment. In this review, we try to summarize and provide the recent progress of aptamer research in the diagnosis and treatment of hematologic malignancies. Until now, 29 aptamer studies were reported in hematologic malignancies, of which 12 aptamers were tested in vivo and the remaining 17 aptamers were only tested in vitro. In this case, 11 aptamers were combined with chemotherapeutic drugs for the treatment of hematologic malignancies, 4 aptamers were used in combination with nanomaterials for the diagnosis and treatment of hematologic malignancies, and some studies used aptamers for the targeted transportation of siRNA and miRNA for targeted therapeutic effects. Their research provides multiple approaches to achieve more targeted goals. These findings show promising and encouraging future for both hematological malignancies basic and clinical trials research.
Funder
Natural Science Foundation of Hunan Province of China
the National Key Research and Development Program of China
the National Natural Science Foundation of China
the Graduate Independent Exploration and Innovation Project of Central South University
Reference186 articles.
1. Uribe-Herranz, M., Klein-Gonzalez, N., Rodriguez-Lobato, L.G., Juan, M., and de Larrea, C.F. (2021). Gut Microbiota Influence in Hematological Malignancies: From Genesis to Cure. Int. J. Mol. Sci., 22.
2. Immunotherapy in hematologic malignancies;Kansara;Curr. Oncol.,2020
3. Non-Hodgkin lymphoma therapy landscape;Chaudhari;Nat. Rev. Drug Discov.,2019
4. Entering the era of targeted therapy for chronic lymphocytic leukemia: Impact on the practicing clinician;Byrd;J. Clin. Oncol.,2014
5. How Does Complement Affect Hematological Malignancies: From Basic Mechanisms to Clinical Application;Luo;Front. Immunol.,2020
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献